Fairmount Funds Discloses 19.99% Stake in Korsana Biosciences After $380M Merger Financing
Summary
Fairmount Funds Management reports a 19.99% stake in Korsana Biosciences after the reverse merger, with $112.5 million invested and significant board influence through Series B preferred stock.
Key Events · Ownership and Investor Activity · CYCN
-
Fairmount Reports 19.99% Ownership
Fairmount Funds Management and affiliates hold 9,103,729 shares of Korsana Biosciences, representing 19.99% of the 45.5 million shares outstanding as of September 8, 2026.
-
$112.5M Total Investment
Fairmount paid $99,999,973 for common stock and pre-funded warrants, plus $12,500,000 for Series B preferred stock, across the merger and pre-closing financing.
-
Series B Preferred Board Control
While at least 30% of original Series B preferred stock remains outstanding, its holders elect four directors who each receive three votes on board matters, giving Fairmount significant governance influence.
-
180-Day Lock-Up
Reporting Persons are subject to 180-day lock-up agreements on most shares, excluding shares purchased in the Korsana Pre-Closing Financing, limiting near-term selling pressure.
Analysis · CYCN · Life Sciences
Fairmount Funds Management and its affiliates now hold 9.1 million shares, or 19.99% of Korsana Biosciences, following the reverse merger and $380 million pre-closing financing. The filing reveals $112.5 million in total capital deployed by Fairmount across common stock, pre-funded warrants, and Series B preferred stock. The Series B preferred stock carries significant governance rights: while at least 30% of the original Series B remains outstanding, its holders elect four directors who each get three votes on board matters. This gives Fairmount substantial influence over the newly merged company's board and strategic direction. The 180-day lock-up on most shares limits near-term selling pressure, but the excluded pre-closing financing shares could become tradable sooner.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYCN was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.7M. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.